Oxford BioDynamics strengthens with senior appointment
Oxford BioDynamics, a biotechnology company that develops precision medicine tests, has appointed Dr Steven Arrivo as Senior Vice President of Business and Corporate Development.
Dr. Arrivo brings over 20 years of science and industry experience along with an established track record in business and corporate development within personalized medicine across big pharma, biotech and molecular diagnostics companies.
He joins from CellCarta Biosciences where he spent five years in Business Development, as Senior Director and Vice President. Prior to that he was at Biodesix and Ventana Medical Systems. Before then, he spent four years at Pfizer in various R&D roles.
Visit Hampshire Biz News for bright, upbeat and positive business news from the county
At OBD, Dr Arrivo's role will be to implement effective marketing and sales strategies for the newly launched EpiSwitch PSE prostate cancer detection test. His specific focus will be to grow sales in the US market, where he has considerable experience of launching products.
Dr Jon Burrows, CEO of Oxford BioDynamics, said: "Having someone of Steve's calibre in the OBD commercial team is a real endorsement of our technology and its potential.
''He has a wealth of experience in this industry and the ideal skill set to drive our commercial efforts with PSE. His leadership and knowledge will be invaluable across all areas of our growing product portfolio."
"While it is currently early days for the PSE test in the market, the signs are promising. We have work to do so establish ourselves fully in the testing market, but appointments of this quality are crucial in strengthening and furthering our progress towards that goal."
Read more - B P Collins names Daniel Johnson as new operations director